HUTCHMED (China) (HCM) Deutsche Bank’s Depositary Receipts Virtual Investor Conference summary

Key product launches and commercial performance

• Fruquintinib (FRUZAQLA) achieved $130 million in sales in H1, with recent approvals in the U.S., Europe, UK, and Japan, and strong market share in China exceeding 40%.

• SULANDA maintains a solid second position in China's neuroendocrine tumor market, benefiting from insurance inclusion and broad patient access.

• Savolitinib, a MET inhibitor for lung cancer, generated $25 million in H1 sales in China and is awaiting pivotal trial data for potential U.S. and global expansion.

• Sovleplenib, targeting immune thrombocytopenia, is filed for approval in China with launch expected in 2025, and shows a 48% durable response rate in late-line patients.

Pipeline development and clinical milestones

• Fruquintinib is being developed for additional indications, including endometrial and renal cell carcinoma, with regulatory filings and data readouts expected by early next year.

• Savolitinib's SAVANNAH trial for second-line lung cancer is expected to report data by year-end, with potential U.S. FDA filing soon after.

• Sovleplenib is also in phase III for warm AIHA, a rare autoimmune anemia with no approved therapies, and may become the first global treatment.

• Additional late-stage assets include HMPL-453 for intrahepatic carcinoma and HMPL-306 for AML, both advancing in registration trials.

Competitive positioning and innovation

• Fruquintinib demonstrates superior efficacy and lower toxicity compared to competitors, driving rapid adoption and inclusion in clinical guidelines.

• Savolitinib is differentiated as a MET-specific therapy, free from chemotherapy, and offers oral administration, targeting a $1 billion market in China and globally.

• Sovleplenib addresses significant unmet needs in ITP and warm AIHA, with a favorable safety profile and potential to expand the treatable patient population.

• The company emphasizes rigorous preclinical selection, high molecular selectivity, and a robust chemistry team to ensure low off-target toxicity.